Cargando…
Interleukin 15 and Eotaxin correlate with the outcome of breast cancer patients vice versa independent of CTC status
BACKGROUND: Circulating tumor cells (CTC) in the peripheral blood in women with breast cancer has been found to be an indicator of prognosis before the start of systemic treatment. The aim of this study is the assessment of specific cytokine profiles as markers for CTC involvement that could act as...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7854415/ https://www.ncbi.nlm.nih.gov/pubmed/32929618 http://dx.doi.org/10.1007/s00404-020-05793-y |
_version_ | 1783646083589603328 |
---|---|
author | Vilsmaier, Theresa Heidegger, Helene Hildegard Schröder, Lennard Trapp, Elisabeth zehni, Alaleh Zati Rack, Brigitte Janni, Wolfgang Mahner, Sven Weissenbacher, Tobias Jeschke, Udo Mumm, Jan-Niclas |
author_facet | Vilsmaier, Theresa Heidegger, Helene Hildegard Schröder, Lennard Trapp, Elisabeth zehni, Alaleh Zati Rack, Brigitte Janni, Wolfgang Mahner, Sven Weissenbacher, Tobias Jeschke, Udo Mumm, Jan-Niclas |
author_sort | Vilsmaier, Theresa |
collection | PubMed |
description | BACKGROUND: Circulating tumor cells (CTC) in the peripheral blood in women with breast cancer has been found to be an indicator of prognosis before the start of systemic treatment. The aim of this study is the assessment of specific cytokine profiles as markers for CTC involvement that could act as independent prognostic markers in terms of survival outcome for breast cancer patients. METHODS: Patients selected for this study were defined as women with breast cancer of the SUCCESS study. A total of 200 patients’ sera were included in this study, 100 patients being positive for circulating tumor cells (CTC) and 100 patients being CTC negative. The matching criteria were histo-pathological grading, lymph node metastasis, hormone receptor status, TNM classification, and patient survival. Commercial ELISA with a multi cytokine/chemokine array was used to screen the sera for Interleukin 15 (IL-15) and eotaxin. RESULTS: Statistically significant concentrations were exposed for IL-15 levels regardless of the CTC-Status, lymph node involvement, or hormone receptor status. Significantly enhanced serum IL-15 concentrations were observed in those patients with worse overall survival (OS) and disease-free survival (DFS). Elevated serum concentrations of IL-15 significantly correlate with patients diagnosed with Grade 3 tumor and worse OS. In contrast, patients with a Grade 3 tumor with a favourable OS and DFS demonstrated significantly decreased IL-15 values. The CTC negative patient subgroup with a favourable OS and DFS, showed statistically significant elevated eotaxin values. CONCLUSION: These findings suggest a potential functional interaction of increased IL-15 concentrations in the peripheral blood of patients with a worse OS and DFS, regardless of prognostic factors at primary diagnosis. The increased levels of the chemokine eotaxin in CTC negative patients and a favourable OS and DFS, on the other hand, suggest that the overexpression inhibits CTCs entering the peripheral blood, thus emphasizing a significant inhibition of circulation specific metastasis. To sum up, IL-15 could be used as an independent prognostic marker in terms of survival outcome for breast cancer patients and used as an early indicator to highlight high-risk patients and consequently the adjustment of cancer therapy strategies. |
format | Online Article Text |
id | pubmed-7854415 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-78544152021-02-08 Interleukin 15 and Eotaxin correlate with the outcome of breast cancer patients vice versa independent of CTC status Vilsmaier, Theresa Heidegger, Helene Hildegard Schröder, Lennard Trapp, Elisabeth zehni, Alaleh Zati Rack, Brigitte Janni, Wolfgang Mahner, Sven Weissenbacher, Tobias Jeschke, Udo Mumm, Jan-Niclas Arch Gynecol Obstet Gynecologic Oncology BACKGROUND: Circulating tumor cells (CTC) in the peripheral blood in women with breast cancer has been found to be an indicator of prognosis before the start of systemic treatment. The aim of this study is the assessment of specific cytokine profiles as markers for CTC involvement that could act as independent prognostic markers in terms of survival outcome for breast cancer patients. METHODS: Patients selected for this study were defined as women with breast cancer of the SUCCESS study. A total of 200 patients’ sera were included in this study, 100 patients being positive for circulating tumor cells (CTC) and 100 patients being CTC negative. The matching criteria were histo-pathological grading, lymph node metastasis, hormone receptor status, TNM classification, and patient survival. Commercial ELISA with a multi cytokine/chemokine array was used to screen the sera for Interleukin 15 (IL-15) and eotaxin. RESULTS: Statistically significant concentrations were exposed for IL-15 levels regardless of the CTC-Status, lymph node involvement, or hormone receptor status. Significantly enhanced serum IL-15 concentrations were observed in those patients with worse overall survival (OS) and disease-free survival (DFS). Elevated serum concentrations of IL-15 significantly correlate with patients diagnosed with Grade 3 tumor and worse OS. In contrast, patients with a Grade 3 tumor with a favourable OS and DFS demonstrated significantly decreased IL-15 values. The CTC negative patient subgroup with a favourable OS and DFS, showed statistically significant elevated eotaxin values. CONCLUSION: These findings suggest a potential functional interaction of increased IL-15 concentrations in the peripheral blood of patients with a worse OS and DFS, regardless of prognostic factors at primary diagnosis. The increased levels of the chemokine eotaxin in CTC negative patients and a favourable OS and DFS, on the other hand, suggest that the overexpression inhibits CTCs entering the peripheral blood, thus emphasizing a significant inhibition of circulation specific metastasis. To sum up, IL-15 could be used as an independent prognostic marker in terms of survival outcome for breast cancer patients and used as an early indicator to highlight high-risk patients and consequently the adjustment of cancer therapy strategies. Springer Berlin Heidelberg 2020-09-14 2021 /pmc/articles/PMC7854415/ /pubmed/32929618 http://dx.doi.org/10.1007/s00404-020-05793-y Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Gynecologic Oncology Vilsmaier, Theresa Heidegger, Helene Hildegard Schröder, Lennard Trapp, Elisabeth zehni, Alaleh Zati Rack, Brigitte Janni, Wolfgang Mahner, Sven Weissenbacher, Tobias Jeschke, Udo Mumm, Jan-Niclas Interleukin 15 and Eotaxin correlate with the outcome of breast cancer patients vice versa independent of CTC status |
title | Interleukin 15 and Eotaxin correlate with the outcome of breast cancer patients vice versa independent of CTC status |
title_full | Interleukin 15 and Eotaxin correlate with the outcome of breast cancer patients vice versa independent of CTC status |
title_fullStr | Interleukin 15 and Eotaxin correlate with the outcome of breast cancer patients vice versa independent of CTC status |
title_full_unstemmed | Interleukin 15 and Eotaxin correlate with the outcome of breast cancer patients vice versa independent of CTC status |
title_short | Interleukin 15 and Eotaxin correlate with the outcome of breast cancer patients vice versa independent of CTC status |
title_sort | interleukin 15 and eotaxin correlate with the outcome of breast cancer patients vice versa independent of ctc status |
topic | Gynecologic Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7854415/ https://www.ncbi.nlm.nih.gov/pubmed/32929618 http://dx.doi.org/10.1007/s00404-020-05793-y |
work_keys_str_mv | AT vilsmaiertheresa interleukin15andeotaxincorrelatewiththeoutcomeofbreastcancerpatientsviceversaindependentofctcstatus AT heideggerhelenehildegard interleukin15andeotaxincorrelatewiththeoutcomeofbreastcancerpatientsviceversaindependentofctcstatus AT schroderlennard interleukin15andeotaxincorrelatewiththeoutcomeofbreastcancerpatientsviceversaindependentofctcstatus AT trappelisabeth interleukin15andeotaxincorrelatewiththeoutcomeofbreastcancerpatientsviceversaindependentofctcstatus AT zehnialalehzati interleukin15andeotaxincorrelatewiththeoutcomeofbreastcancerpatientsviceversaindependentofctcstatus AT rackbrigitte interleukin15andeotaxincorrelatewiththeoutcomeofbreastcancerpatientsviceversaindependentofctcstatus AT janniwolfgang interleukin15andeotaxincorrelatewiththeoutcomeofbreastcancerpatientsviceversaindependentofctcstatus AT mahnersven interleukin15andeotaxincorrelatewiththeoutcomeofbreastcancerpatientsviceversaindependentofctcstatus AT weissenbachertobias interleukin15andeotaxincorrelatewiththeoutcomeofbreastcancerpatientsviceversaindependentofctcstatus AT jeschkeudo interleukin15andeotaxincorrelatewiththeoutcomeofbreastcancerpatientsviceversaindependentofctcstatus AT mummjanniclas interleukin15andeotaxincorrelatewiththeoutcomeofbreastcancerpatientsviceversaindependentofctcstatus AT interleukin15andeotaxincorrelatewiththeoutcomeofbreastcancerpatientsviceversaindependentofctcstatus |